ReCor Medical: Resurrecting the Renal Denervation Market

article image

ReCor Medical is conducting clinical trials with its Paradise ultrasound renal denervation system and is moving closer to a US PMA filing, a goal it hopes to reach in 2022. We speak with President and CEO Andrew Weiss about the company’s role in the rebirth of RDN.

While Medtronic plc continues to progress with its radiofrequency renal denervation (RDN) technology, the company’s primary competitor, ReCor Medical Inc. (which merged with Otsuka Holdings in 2018), is pinning its RDN hopes on the Paradise system, a balloon catheter device that utilizes ultrasound energy to ablate the sympathetic nerves that reside in the renal arteries.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: